AbbVie (NYSE: ABBV) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for a combination treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE